Orthogon Therapeutics announced the closing of an oversubscribed financing round, exceeding its $5M target. The funding will accelerate the development of its first-in-class treatments for managing BK virus reactivation in transplant patients.

Orthogon Therapeutics is a privately held R&D company. Orthogon uses structure-based drug design and biophysics to successfully optimize drugs that bind selectively and safely neutralize target proteins that have been considered difficult to “drug”. The Company was founded by a veteran biotech entrepreneur and experienced drug discovery scientists with a mission to prolong and improve patient quality of life.

orthogontherapeutics.com

Biotechnology

Science And Engineering

Orthogon Therapeutics raised $5.2M in a funding round to advance its first oral therapy for BK Polyomavirus.

Description

Company Information

Related People

Orthogon Therapeutics raised $5.2M in a funding round to advance its first oral therapy for BK Polyomavirus.

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Company Information